---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001689"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:48:32.993917+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo

## Summary
- Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.
- Cash, equivalents and securities $52.0M as of Dec 31, 2024, up from $27.1M, with runway into Q1 2026.
- Atopic dermatitis Phase 1 cohorts 1-2: 26% of soquelitinib patients achieved IGA 0/1, 37% EASI 75 vs 0% placebo.
- Phase 3 registrational trial of soquelitinib in PTCL is enrolling; Phase 2 ALPS trial initiated under NIAID.
- Approximately $18.6M cash from early exercise of 5.3M warrants; 11.8M warrants remain outstanding.

## SEC filing metadata
- accession: 0001171843-25-001689
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/0001171843-25-001689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/f8k_032525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001689
- JSON: https://secwatch.observer/filing/0001171843-25-001689.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.